Organogenesis Inc.

Organogenesis Inc., headquartered in Canton, Massachusetts, manufactures and delivers advanced wound care and regenerative medicine products to federal healthcare agencies as a prime contractor on delivery orders and indefinite-delivery vehicles, competing without set-aside protections in the open commercial market. The company is a for-profit manufacturer specializing in concrete product categories: allograft skin substitutes (APLIGRAF), amniotic membrane wound matrices (PURAPLY family, including PURAPLY AM, PURAPLY XT, PURAPLY SX, PURAPLY MZ, and PURAPLY MZ micronized formulations), surgical implants, and related tissue regeneration solutions for wound treatment and surgical repair.

Organogenesis operates as a 100% prime contractor with no subcontract exposure in its federal footprint. The company holds three major indefinite-delivery vehicles anchoring its federal business. The Defense Logistics Agency Troop Support Medical awarded a $49.5 million multiple-award indefinite delivery contract running through June 2026, designated as a total small business set-aside at award but now generating delivery orders without set-aside designation. The Department of Veterans Affairs Headquarters awarded a $25 million single-award indefinite delivery contract for Surgical Implant Next Generation products through September 2026, with a $20 million firm fixed-price delivery order executed in the first year. The VA also issued a Federal Supply Schedule contract (FSS-65-II-A, Medical Equipment and Supplies) with a $2.6 million ceiling through July 2031. Representative delivery orders across these vehicles include a $2,479.90 APLIGRAF order from DLA dated November 2024, an $8,500 PURAPLY AM XT fenestrated dressing order from DLA dated August 2025, and a $17.82 thousand PURAPLY SX 6CM x 9CM order from DLA dated September 2025.

Customer concentration is fragmented across federal healthcare systems. The top five customers by award count cover only 33% of recent awards. By absolute order count, the Defense Logistics Agency Troop Support Medical dominates with 145 awards worth $49.9 million combined potential value, followed by distributed procurement across multiple VA Veterans Integrated Service Network (VISN) regions: VISN 6 (112 awards, $563 thousand), VISN 4 (97 awards, $578 thousand), VISN 16 (95 awards, $586 thousand), and VISN 2 (80 awards, $354 thousand). By potential value, VA VISN 12 leads with 44 awards valued at $112.8 million combined potential value, followed by DLA at $49.9 million. The VA's distributed regional procurement structure creates a high-touch sales footprint requiring engagement across multiple service network purchasing offices. Of the $2.3 billion in combined potential value across all 1,585 prime awards, only $7.9 million is currently obligated (0.3%), indicating the bulk of the portfolio consists of standing IDVs and supply schedules generating individual delivery orders as customer demand materializes.

Activity has accelerated sharply over the past three years. Organogenesis recorded 2 awards in 2022, 7 in 2023, 61 in 2024, 73 in 2025, and 2 awards year-to-date in 2026, reflecting the maturation of its DLA and VA vehicle positions. The company's work is classified overwhelmingly under PSC Medical and Surgical Instruments, Equipment, and Supplies (1,367 awards) and NAICS categories centered on surgical appliance manufacturing (386 awards) and medical equipment and supplies merchant wholesaling (454 awards). Place of performance is concentrated at the Canton, Massachusetts headquarters for manufacturing.

Organogenesis competes as a standard commercial vendor, not under set-aside protections, despite the underlying DLA multiple-award contract being awarded as a total small business set-aside. This posture reflects the company's positioning as an established for-profit manufacturer with commercial scale sufficient to compete full-and-open. The vendor's federal footprint is entirely dependent on its standing vehicle relationships with DLA Troop Support Medical and the VA; the company has not pursued or been awarded major prime IDIQ vehicles from other agencies or government-wide acquisition contracts.

We are a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Our products have been shown through clinical studies to support and in some cases accelerate tissue healing and improve patient outcomes. We are advancing the standard of care in the healing process through multiple breakthroughs in tissue engineering and cell therapy. Our solutions address large and growing markets driven by aging demographics and increases in comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease and smoking. We offer our differentiated products and in-house customer support to a wide range of health care customers. Our mission is to provide integrated healing solutions that substantially improve medical outcomes and the lives of patients while lowering the overall cost of care. For more info, please visit us at http://www.organogenesis.com.